Results 11 to 20 of about 8,310 (238)

RWE in Europe Paper III: A Roadmap for RWE

, 2017
Real world evidence (RWE) has been touted as a remedy for current market access issues, facilitating quicker approvals and increased odds of reimbursement at a good price. It is therefore an attractive avenue for pursuit for manufacturers today. This paper, the third in a series looking at the use of RWE in Europe, outlines the discussions held between
Gill, Jennifer, Albanell, Joan, Avouac, Bernard, Berger, Karin, Boerlum Kristensen, Finn, Bucher, Heiner, Duncombe, Robert, Fink-Wagner, Antje-Henriette, Hutton, John, Jahnz-Różyk, Karina, Kossler, Ingrid, Podrazilova, Katerina, Spandonaro, Federico, Thomas, Michael, Vaz-Carneiro, Antonio, Wartenberg, Markus, Kanavos, Panos   +16 more
core   +4 more sources

Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? [version 1; referees: 2 approved]

F1000Research, 2018
Stakeholders in healthcare are increasingly turning to real world evidence (RWE) to inform their decisions, alongside evidence from randomized controlled trials.
Sajan Khosla, Robert White, Jesús Medina, Mario Ouwens, Cathy Emmas, Tim Koder, Gary Male, Sandra Leonard   +7 more
doaj   +2 more sources

STaRT-RWE: structured template for planning and reporting on the implementation of real-world evidence studies

Реальная клиническая практика: данные и доказательства, 2022
Aim. To highlight the features of STaRT-RWE (a structured template for planning and reporting on research in real clinical practice — RWE).Materials and methods.
S. L. Plavinskij, A. N. Barinova
doaj   +3 more sources

Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model

Frontiers in Medicine, 2021
Real world evidence (RWE) and real-world data (RWD) are drawing ever-increasing attention in the pharmaceutical industry and drug regulatory authorities (DRAs) all over the world due to their paramount role in supporting drug development and regulatory ...
Meng Li, Shengqi Chen, Yunfeng Lai, Zuanji Liang, Jiaqi Wang, Junnan Shi, Haojie Lin, Dongning Yao, Hao Hu, Carolina Oi Lam Ung   +9 more
doaj   +1 more source

Methods for the inclusion of real-world evidence in network meta-analysis

BMC Medical Research Methodology, 2021
Background Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs).
David A. Jenkins, Humaira Hussein, Reynaldo Martina, Pascale Dequen-O’Byrne, Keith R. Abrams, Sylwia Bujkiewicz   +5 more
doaj   +1 more source

Optimizing Use of Real-World Data in Regulatory Decision Making for Medical Devices Used in Surgical Procedures. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Purpose In the United States, the Food and Drug Administration has provided guidance on the contexts in which real‐world evidence (RWE) can be used to support regulatory decisions for medical devices. Methods In this paper, we review different sources of real‐world data (RWD) for medical devices used in surgical procedures and how to optimize ...
Cafri G, Bourgeois F, Coplan P.
europepmc   +2 more sources

Teaching Real-World Evidence: Protocol for a Systematic Review

JMIR Research Protocols, 2020
BackgroundReal-world evidence (RWE) refers to observational health care data beyond clinical trial data. It holds the promise of transforming health care as a new form of evidence to support decision makers in making decisions when developing and ...
Lam, Ching, van Velthoven, Michelle Helena, Chaudhury, Hassan, Meinert, Edward   +3 more
doaj   +1 more source

Using artificial intelligence to identify patients with migraine and associated symptoms and conditions within electronic health records

BMC Medical Informatics and Decision Making, 2023
Background Real-world evidence (RWE)—based on information obtained from sources such as electronic health records (EHRs), claims and billing databases, product and disease registries, and personal devices and health applications—is increasingly used to ...
Daniel Riskin, Roger Cady, Anand Shroff, Nada A. Hindiyeh, Timothy Smith, Steven Kymes   +5 more
doaj   +1 more source

Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? [version 2; referees: 2 approved]

F1000Research, 2018
Stakeholders in healthcare are increasingly turning to real world evidence (RWE) to inform their decisions, alongside evidence from randomized controlled trials.
Sajan Khosla, Robert White, Jesús Medina, Mario Ouwens, Cathy Emmas, Tim Koder, Gary Male, Sandra Leonard   +7 more
doaj   +1 more source

Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making

Clinical Medicine Insights: Cardiology, 2020
Real-world evidence (RWE) provides a potential rich source of additional information to the body of data available from randomized clinical trials (RCTs), but there is a need to understand the strengths and limitations of RWE before it can be applied to ...
Todd C Villines, Mark J Cziraky, Alpesh N Amin   +2 more
doaj   +1 more source